TrialAmerican journal of clinical dermatology2025

Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment.

Brett King et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.